15 completed, 2 terminated, 1 unknown. 18 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 15, Terminated 2, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow Achieve Life Sciences: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Cytisinicline for Vaping Cessation in Adult Smokers cytisinicline, Placebo, Behavioral support - Vaping, E-Cig Use | Phase 2 | Completed | Achieve Life Sciences | 160 | 2022-07-13 | 2026-01-14 |
| Trial of Cytisine in Adult Smokers Cytisine, Placebo Comparator, Behavioral support - Smoking Cessation | Phase 2 | Completed | Achieve Life Sciences | 254 | 2018-11-13 | 2020-05-18 |
| A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers Cytisine - Smoking Cessation | Phase 1 / Phase 2 | Terminated | Achieve Life Sciences | 26 | 2017-10-06 | 2019-10-21 |
| Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers Apatorsen (OGX-427), Gemcitabine, Carboplatin - Squamous Cell Lung Cancer | Phase 2 | Unknown | Queen Mary University of London | 140 | 2014-06-01 | 2017-08-22 |
| Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer OGX-427, Placebo - Pancreatic Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 132 | 2013-09-01 | 2017-05-16 |
| Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer OGX-427, Placebo - Non Squamous Non Small Cell Lung Cancer | Phase 2 | Completed | SCRI Development Innovations, LLC | 155 | 2013-07-01 | 2018-06-08 |
| Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer OGX-427, Docetaxel - Bladder Cancer, Urothelial Carcinoma | Phase 2 | Completed | Noah Hahn, M.D. | 200 | 2013-04-01 | 2022-07-11 |
| OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone OGX-427, Abiraterone Acetate, Prednisone - Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer | Phase 2 | Terminated | Costantine Albany | 72 | 2012-12-01 | 2022-07-11 |
| A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer OGX-427 600 mg, OGX-427 1000 mg, Placebo - Urologic Neoplasms, Metastatic Bladder Cancer | Phase 2 | Completed | Achieve Life Sciences | 183 | 2011-10-01 | 2016-10-07 |
| OGX-427 in Castration Resistant Prostate Cancer Patients OGX-427, Prednisone - Castration Resistant Prostate Cancer | Phase 2 | Completed | British Columbia Cancer Agency | 74 | 2010-09-01 | 2019-02-15 |
| Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC custirsen (OGX-011)/mitoxantrone, custirsen (OGX-011)/docetaxel - Prostate Cancer | Phase 2 | Completed | Achieve Life Sciences | 70 | 2006-07-01 | 2012-10-05 |
| A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) custirsen sodium - Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Achieve Life Sciences | 85 | 2004-11-01 | 2012-02-06 |
| Evaluation of Safety and Efficacy of TOCOSOL(R) Paclitaxel as Initial Treatment for Metastatic Breast Cancer TOCOSOL(R) Paclitaxel - Breast Cancer | Phase 2 | Completed | Achieve Life Sciences | 47 | 2004-10-01 | 2009-06-04 |
| TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium TOCOSOL Paclitaxel - Bladder Neoplasms, Ureteral Neoplasms | Phase 2 | Completed | Achieve Life Sciences | 44 | 2003-11-01 | 2009-06-04 |
| Safety and Efficacy of S-8184 in Treatment of Locally Advanced, Metastatic, or Recurrent TCC of the Urothelium S-8184 Paclitaxel Injectable Emulsion, Experimental Arm: TOCOSOL Paclitaxel - Urologic Neoplasms | Phase 2 | Completed | Achieve Life Sciences | 27 | 2002-04-01 | 2009-06-04 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Relapsed Stage IIIB or IV Non Small Cell Lung Cancer S-8184 Paclitaxel Injectable Emulsion - Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Achieve Life Sciences | 52 | 2002-04-01 | 2009-06-04 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Ovarian Cancer S-8184 Paclitaxel Injectable Emulsion - Ovarian Cancer | Phase 2 | Completed | Achieve Life Sciences | 52 | 2002-03-01 | 2009-06-04 |
| Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma S-8184 Paclitaxel Injectable Emulsion - Colorectal Adenocarcinoma | Phase 2 | Completed | Achieve Life Sciences | 28 | 2002-03-01 | 2009-06-04 |
Carcinoma, Non-Small-Cell Lung (3) · Carcinoma, Transitional Cell (3) · Prostatic Neoplasms (3) · Urinary Bladder Neoplasms (3) · Neoplasm Metastasis (2) · Smoking Cessation (2) · Urologic Neoplasms (2) · Breast Neoplasms (1) · Lung Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Vaping (1)
apatorsen (7) · cytisine (3) · Behavior Therapy (2) · Carboplatin (2) · Gemcitabine (2) · OGX-011 (2) · Prednisone (2) · Abiraterone Acetate (1) · Cisplatin (1) · Docetaxel (1) · Paclitaxel (1)
United States (10) · Canada (5) · Russia (3) · United Kingdom (2) · France (1) · Germany (1) · Italy (1) · Poland (1) · Spain (1)
Annelize Koch, MD (1) · Constantine Albany, M.D. (1) · Daniel Cain, Vice-President Clinical Research (1) · Daniel Petrylak, MD (1) · David R. Spigel, M.D. (1) · Eric Winquist, MD, MSc (1) · Fred Saad, MD, FRCS (1) · Janessa Laskin, M.D. (1) · Johanna Bendell, M.D. (1) · Kim N Chi, MD (1) · Mitchell Nides, PhD (1) · Noah Hahn, M.D. (1) · Peter Schmid, Prof. (1)
PMID 21788353, PMID 22198426, PMID 24156019, PMID 28935773, PMID 38709500